Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia

Andrea Bacigalupo, Alida Dominietto, Sarah Pozzi, Maurizio Miglino, Flavio Albarracin, Giovanna Piaggio, Francesca Bertolotti

Research output: Contribution to journalArticle

Abstract

Minimal residual disease (MRD) was monitored in 80 patients with acute lymphoid (ALL, n=44) or myeloid (AML, n=36) leukemia, undergoing allogeneic haemopoietic stem cell transplantations. MRD markers were IgH-VDJ and TCR gene rearrangement for ALL, and Wilm's Tumor (WT1) expression for AML. The overall cumulative incidence (CI) of MRD was positive in 45% and the CI of hematologic relapse was 24% (36% in MRD+ vs. 16% in MRD patients, p=0.03). The median interval from transplant to first MRD positivity was 120 days and to hematologic relapse 203 days. Patients were divided in 3 MRD groups: MRD (n=44), MRD+ given donor lymphocyte infusions (DLI) (n=17) and MRD+ not given DLI (n=19): leukemia relapse rates in these 3 groups were 16%, 6% and 63%, respectively (p

Original languageEnglish
Pages (from-to)42-44
Number of pages3
JournalRevista Brasileira de Hematologia e Hemoterapia
Volume30
Issue numberSUPPL. 2
DOIs
Publication statusPublished - Jun 2008

Fingerprint

Residual Neoplasm
Leukemia
Tissue Donors
Lymphocytes
Therapeutics
Recurrence
Gene Rearrangement
Incidence
Stem Cell Transplantation
Transplants

Keywords

  • Acute lymphoid leukemia
  • Acute myeloid leukemia
  • Allogeneic hematopoietic stem cell transplantation
  • Donor lymphocyte infusion
  • Minimal residual disease

ASJC Scopus subject areas

  • Hematology

Cite this

Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia. / Bacigalupo, Andrea; Dominietto, Alida; Pozzi, Sarah; Miglino, Maurizio; Albarracin, Flavio; Piaggio, Giovanna; Bertolotti, Francesca.

In: Revista Brasileira de Hematologia e Hemoterapia, Vol. 30, No. SUPPL. 2, 06.2008, p. 42-44.

Research output: Contribution to journalArticle

Bacigalupo, Andrea ; Dominietto, Alida ; Pozzi, Sarah ; Miglino, Maurizio ; Albarracin, Flavio ; Piaggio, Giovanna ; Bertolotti, Francesca. / Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia. In: Revista Brasileira de Hematologia e Hemoterapia. 2008 ; Vol. 30, No. SUPPL. 2. pp. 42-44.
@article{da92c996617242e9918613ddb4cca8ad,
title = "Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia",
abstract = "Minimal residual disease (MRD) was monitored in 80 patients with acute lymphoid (ALL, n=44) or myeloid (AML, n=36) leukemia, undergoing allogeneic haemopoietic stem cell transplantations. MRD markers were IgH-VDJ and TCR gene rearrangement for ALL, and Wilm's Tumor (WT1) expression for AML. The overall cumulative incidence (CI) of MRD was positive in 45{\%} and the CI of hematologic relapse was 24{\%} (36{\%} in MRD+ vs. 16{\%} in MRD patients, p=0.03). The median interval from transplant to first MRD positivity was 120 days and to hematologic relapse 203 days. Patients were divided in 3 MRD groups: MRD (n=44), MRD+ given donor lymphocyte infusions (DLI) (n=17) and MRD+ not given DLI (n=19): leukemia relapse rates in these 3 groups were 16{\%}, 6{\%} and 63{\%}, respectively (p",
keywords = "Acute lymphoid leukemia, Acute myeloid leukemia, Allogeneic hematopoietic stem cell transplantation, Donor lymphocyte infusion, Minimal residual disease",
author = "Andrea Bacigalupo and Alida Dominietto and Sarah Pozzi and Maurizio Miglino and Flavio Albarracin and Giovanna Piaggio and Francesca Bertolotti",
year = "2008",
month = "6",
doi = "10.1590/S1516-84842008000600011",
language = "English",
volume = "30",
pages = "42--44",
journal = "Revista Brasileira de Hematologia e Hemoterapia",
issn = "1516-8484",
publisher = "Sociedade Brasileira de Hematologia e Hemoterapia",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia

AU - Bacigalupo, Andrea

AU - Dominietto, Alida

AU - Pozzi, Sarah

AU - Miglino, Maurizio

AU - Albarracin, Flavio

AU - Piaggio, Giovanna

AU - Bertolotti, Francesca

PY - 2008/6

Y1 - 2008/6

N2 - Minimal residual disease (MRD) was monitored in 80 patients with acute lymphoid (ALL, n=44) or myeloid (AML, n=36) leukemia, undergoing allogeneic haemopoietic stem cell transplantations. MRD markers were IgH-VDJ and TCR gene rearrangement for ALL, and Wilm's Tumor (WT1) expression for AML. The overall cumulative incidence (CI) of MRD was positive in 45% and the CI of hematologic relapse was 24% (36% in MRD+ vs. 16% in MRD patients, p=0.03). The median interval from transplant to first MRD positivity was 120 days and to hematologic relapse 203 days. Patients were divided in 3 MRD groups: MRD (n=44), MRD+ given donor lymphocyte infusions (DLI) (n=17) and MRD+ not given DLI (n=19): leukemia relapse rates in these 3 groups were 16%, 6% and 63%, respectively (p

AB - Minimal residual disease (MRD) was monitored in 80 patients with acute lymphoid (ALL, n=44) or myeloid (AML, n=36) leukemia, undergoing allogeneic haemopoietic stem cell transplantations. MRD markers were IgH-VDJ and TCR gene rearrangement for ALL, and Wilm's Tumor (WT1) expression for AML. The overall cumulative incidence (CI) of MRD was positive in 45% and the CI of hematologic relapse was 24% (36% in MRD+ vs. 16% in MRD patients, p=0.03). The median interval from transplant to first MRD positivity was 120 days and to hematologic relapse 203 days. Patients were divided in 3 MRD groups: MRD (n=44), MRD+ given donor lymphocyte infusions (DLI) (n=17) and MRD+ not given DLI (n=19): leukemia relapse rates in these 3 groups were 16%, 6% and 63%, respectively (p

KW - Acute lymphoid leukemia

KW - Acute myeloid leukemia

KW - Allogeneic hematopoietic stem cell transplantation

KW - Donor lymphocyte infusion

KW - Minimal residual disease

UR - http://www.scopus.com/inward/record.url?scp=55949084019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55949084019&partnerID=8YFLogxK

U2 - 10.1590/S1516-84842008000600011

DO - 10.1590/S1516-84842008000600011

M3 - Article

AN - SCOPUS:55949084019

VL - 30

SP - 42

EP - 44

JO - Revista Brasileira de Hematologia e Hemoterapia

JF - Revista Brasileira de Hematologia e Hemoterapia

SN - 1516-8484

IS - SUPPL. 2

ER -